How much did Chai Discovery raise and at what valuation?

Chai Discovery raised a $400M Series C at a reported $3.8 billion valuation in early August 2026. The round was led by Index Ventures with participation from Kleiner Perkins and Sequoia Capital, alongside new pharma collaborations with Novartis and argenx.

What does Chai Discovery do?

Chai Discovery is a San Francisco AI drug-design company building structure-prediction and molecular-design models (its Chai-3 system) for biologics and small molecules. It partners with large pharma — Lilly, Pfizer, Novartis, and argenx — to accelerate discovery, competing in the same space as AlphaFold-derived tools.

Why is AI drug discovery attracting megarounds in 2026?

In a tighter 2026 venture market with the fewest healthcare deals in a decade, capital concentrated into a few large AI drug-discovery bets. Investors see structure-prediction and generative molecular design as the highest-leverage application of AI, driving $400M+ rounds despite overall deal scarcity.

Quick Answer

Chai Discovery Raises $400M: AI Drug Design (2026)

Published: August 6, 2026

The Short Answer

Chai Discovery raised a $400M Series C at a ~$3.8B valuation in early August 2026, led by Index Ventures with Kleiner Perkins and Sequoia Capital. It landed alongside new pharma collaborations with Novartis and argenx — one of the largest AI-drug-design rounds of the year.

The Deal

	Detail
Company	Chai Discovery (San Francisco)
Round	Series C, $400M
Valuation	~$3.8B (reported)
Lead	Index Ventures
Other investors	Kleiner Perkins, Sequoia Capital
New partners	Novartis, argenx

What Chai Does

Chai builds AI models for molecular structure prediction and design — its Chai-3 system targets biologics and small molecules. Where AlphaFold cracked protein folding, Chai’s pitch is generative design of candidate molecules, plugged directly into pharma pipelines. It already counts Lilly, Pfizer, Novartis, and argenx among collaborators.

Why It Matters

Capital concentration: 2026 has been the tightest healthcare-venture market in over a decade (fewest deals), yet AI drug discovery pulled megarounds. Investors are funneling scarce capital into a few high-conviction AI bets.
Validation of the category: A $3.8B valuation for structure-prediction/design signals that AI-native biotech is now a distinct, fundable category — not a research curiosity.
Pharma buy-in: Novartis and argenx deals show large pharma treating AI design as production infrastructure, not a pilot.

The Watch-Out

Valuations in AI drug discovery are running ahead of clinical readouts. The proof will be AI-designed candidates advancing through trials — the pipeline, not the round size, is the real benchmark. Chai’s models still have to convert compute into approved drugs.

Sources

IntuitionLabs — Chai Discovery $400M / $3.8B analysis: intuitionlabs.ai
Neo & Noteworthy — Chai’s $400M Series C with Novartis/argenx: neo.substack.com
AlleyWatch — July 2026 US VC funding report: alleywatch.com